Update from the PSMA-dRT trial: A randomized phase III trial of PSMA-PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer.

被引：0
|
作者：
Nikitas, John
Lam, Ethan C.
Booker, Kiara M.
Fendler, Wolfgang P.
Eiber, Matthias
Hadaschik, Boris A.
Herrmann, Ken
Hirmas, Nader
Lanzafame, Helena
Stuschke, Martin
Czernin, Johannes
Steinberg, Michael L.
Nickols, Nicholas George
Kishan, Amar Upadhyaya
Calais, Jeremie
机构：
[1] Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA USA
[2] Univ Calif Los Angeles, Ahmanson Translat Theranost Div, Los Angeles, CA USA
[3] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Nucl Med, Essen, Germany
[4] Tech Univ Munich, Dept Nucl Med, Munich, Germany
[5] Univ Duisburg Essen, Dept Urol, Essen, Germany
[6] Univ Hosp Essen, German Canc Consortium DKTK, Essen, Germany
[7] Univ Duisburg Essen, Dept Nucl Med, Essen, Germany
[8] Univ Duisburg Essen, Univ Med Essen, Dept Radiotherapy, Essen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
613-615-646-3281-7408-2399; 261-137; 283-183-180; 613-545; 261-436-2730; 14; 6; 3; 3617; 2;
D O I：
10.1200/JCO.2024.42.4_suppl.291
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：291 / 291
页数：1
相关论文
共 50 条
  • [21] 68Ga-PSMA-11 PET/MRI in Primary Intermediate/High-Risk Prostate Cancer
    Park, Sonya
    Zacharias, Claudia
    Harrison, Caitlyn
    Giesel, Frederik
    Iagaru, Andrei
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [22] PREDICTIVE VALUE OF PSMA PET/CT IMAGING FOR PRIMARY STAGING OF INTERMEDIATE AND HIGH-RISK PROSTATE CANCER
    Campobasso, Davide
    Guarino, Giulio
    Scarlattei, Maura
    Ziglioli, Francesco
    Ferretti, Stefania
    Dinale, Francesco
    Badari, Giorgio
    Gasparro, Donatello
    Ruffini, Livia
    Maestroni, Umberto Vittorio
    ANTICANCER RESEARCH, 2021, 41 (10) : 5277 - 5278
  • [23] PSMA-targeted PET with [68Ga]Ga-P16-093: Initial evaluation in intermediate-risk and high-risk prostate cancer patients prior to prostatectomy
    Green, Mark
    Bahler, Clint
    Tann, Mark
    Hutchins, Gary
    Mathias, Carla
    Territo, Wendy
    Whaley, Rumeal
    Cheng, Liang
    Alexoff, David
    Eckelman, William
    Kung, Hank
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [24] Impact of definitive radiotherapy on metabolic response measured with 68Ga-PSMA-PET/CT in patients with intermediate-risk prostate cancer
    Onal, Cem
    Guler, Ozan C.
    Torun, Nese
    Elmali, Aysenur
    Sutera, Philip
    Deek, Matthew P.
    Reyhan, Mehmet
    Yavuz, Melek
    Tran, Phuoc T.
    PROSTATE, 2024, 84 (15): : 1366 - 1374
  • [25] Survival Outcomes in Men with Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Prostate-Only versus Whole Pelvic Radiation Therapy
    Andruska, Neal
    Fischer-Valuck, Benjamin W.
    Waters, Michael
    Diaz, Elizabeth Juarez
    Agabalogun, Temitope
    Kim, Eric H.
    Smith, Zachary L.
    Brenneman, Randall J.
    Gay, Hiram A.
    Andriole, Gerald L.
    Michalski, Jeff M.
    Baumann, Brian C.
    JOURNAL OF UROLOGY, 2022, 207 (06): : 1227 - 1234
  • [26] PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging
    Holzgreve, Adrien
    Armstrong, Wesley R.
    Clark, Kevyn J.
    Benz, Matthias R.
    Smith, Clayton P.
    Djaileb, Loic
    Gafita, Andrei
    Thin, Pan
    Nickols, Nicholas G.
    Kishan, Amar U.
    Rettig, Matthew B.
    Reiter, Robert E.
    Czernin, Johannes
    Calais, Jeremie
    JAMA NETWORK OPEN, 2025, 8 (01)
  • [27] The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients-towards a tumor volume-based risk stratification
    Hagens, Marinus J.
    Luining, Wietske I.
    Boeve, Liselotte M. S.
    Knol, Remco J. J.
    Roeleveld, Ton A.
    Srbljin, Sandra
    Weltings, Saskia
    Koppes, Jose C. C.
    Oprea-Lager, Daniela E.
    Vis, Andre N.
    van Leeuwen, Pim J.
    van der Poel, Henk G.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2024,
  • [28] Reply to comment on: Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial
    Nabid, Abdenour
    Souhami, Luis
    EUROPEAN JOURNAL OF CANCER, 2022, 167 : 166 - 167
  • [29] Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial
    Macias, Victor A.
    Barrera-Mellado, Inmaculada
    BJU INTERNATIONAL, 2020, 125 (02) : 215 - 225
  • [30] PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review
    Lars J. Petersen
    Helle D. Zacho
    Cancer Imaging, 20
12345